제테마

216080KOSDAQ의료용품 및 기타 의약 관련제품 제조업

51.6 / 100

Reference Date: 2026-06-10

Financial Score14.0 / 40

News Sentiment20.6 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Plunged 25.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Jetema develops and manufactures biopharmaceuticals based on hyaluronic acid fillers and botulinum toxin, as well as tissue sutures and lifting threads, expanding into both aesthetic and therapeutic markets. Key products like Jetema Dermal Toxin, which received domestic approval in 2024, are driving growth, with global expansion accelerated through licensing agreements with partners in Brazil, China, and Thailand.

Number of Employees

244people

Average Salary

4.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 19.194.0Point

PBR

2.77Industry Average 1.300.0Point

2.1x industry avg (risky)

ROE

-10.91Industry Average -4.893.5Point

2.2x industry avg (excellent)

Debt Ratio

92.88Industry Average 6.860.0Point

13.5x industry avg (risky)

Trend 2023~20256.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲14.5% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲24.5% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 2.1% (declining, 3yr)

Detailed News Sentiment

4 totalPositive 4Neutral 0Negative 0Average Sentiment Score 82.5

Positive
제테마, 경희대 약학대학 장학금 수여…산학 교류 프로그램도 진행
제테마의 경희대학교와의 산학 협력 강화로 인해 기업 이미지 개선 및 인재 육성에 긍정적 영향 기대.
Positive
제테마, 보툴리눔 톡신 中 3상 CSR 승인…중국 사업 확대 기대감↑
제테마의 중국 임상 3상 성공으로 중국 시장 진출 기대감이 높아져 긍정적인 영향을 받음.
Positive
제테마, 보툴리눔 톡신 중국 임상 3상 CSR 승인
제테마의 중국 임상 3상 CSR 승인으로 보툴리눔 톡신 시장 진출 기대감 상승.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 4,825Won52-week high 10,89052-week low 4,825

1-month return0.0Point

1m -25.65% (strong drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-06-04
Neutral투자판단관련주요경영사항(임상시험결과) (제테마더톡신주100단위(JTM201) 중국 임상 3상 1단계 결과 )2026-05-29
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-28
Neutral분기보고서 (2026.03)2026-05-15
Neutral[기재정정]주식매수선택권부여에관한신고2026-05-13